Navigation Links
Treating eye diseases with anti-VEGF therapies may have side effects
Date:1/11/2013

Rockville, MD A new Investigative Ophthalmology & Visual Science (IOVS) article reveals that increasingly aggressive therapies that block VEGF could cause damage in treating eye diseases. Scientists discovered inhibiting anti-VEGF might have a harmful effect on the tissue responsible for producing the fluid that bathes the eye, medically termed the ciliary body.

"Very little is known about the factors that regulate the integrity and function of this tissue [the ciliary body] in the adult," said author Patricia A. D'Amore, PhD, of Schepens Eye Research Institute/Massachusetts Eye and Ear. "Our finding indicates that VEGF-A is at least one of the molecules that play a role in keeping the ciliary body healthy and functioning properly."

In the study, Expression and role of VEGF-A in the Ciliary Body, investigators simulated the VEGF-A activity in adult mice and found that blocking the protein decreased the intraocular pressure, an unexpected side effect that impaired the ciliary body.

Several anti-VEGF-A therapies are currently being widely and successfully used for the treatment of eye diseases like wet macular degeneration, diabetic macular edema and retinopathy of prematurity. D'Amore agrees that there is no evidence to indicate that the manner in which these drugs are being administered interferes with the ciliary body. "However, there is a move toward developing methods to continuously deliver anti-VEGF to the eye and to have drugs that are more potent inhibitors of VEGF," she said. "I would be concerned that more aggressive VEGF inhibition in the eye would have deleterious effects on the ciliary body."

The research team's investigation of anti-VEGF-A on the ciliary body was the result of prior studies that found blocking VEGF can lead to the degeneration of capillary beds, particularly capillaries that have specializations called fenestrations like the ones found in the ciliary body. These include whole body VEGF bl
'/>"/>

Contact: Katrina Norfleet
knorfleet@arvo.org
240-221-2924
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study Suggests Treating Dyslexia Before Kids Learn to Read
2. New standards for treating traumatic shoulder injuries to improve patient care
3. Treating childhood obesity: A family affair
4. Unique physiology key to diagnosing and treating diabetes in Asian populations
5. Studies See Advances in Detecting, Treating Pancreatic Cancer
6. 1 size doesnt fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
7. Nanomedicines promise fewer side effects in treating cancer
8. Mount Sinai researchers develop a multi-target approach to treating tumors
9. A non-antibiotic approach for treating urinary tract infections
10. UT Southwestern study shows treating diabetes early, intensively is best strategy
11. Researchers report success in treating autism spectrum disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... SuiteRx, innovative leaders in pharmacy ... pharmacy operations, announces the most recent positioning of SuiteRx CEO, Nicholas Zener Pharm. ... at the Venetian Las Vegas, Nevada. During this event, SuiteRx will be ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Collaborative ... the New York Community Trust. The grant will allow CCF to improve quality of ... practices. , CCF was formed to respond to many changes in New York’s Medicaid ...
(Date:7/1/2015)... ... , ... Did you know that infertility in men is more common than ... Fertility Center of Texas (AFCT) would like to talk about some natural ways to ... to be a “woman’s issue,” male fertility factors can play a role in about ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... said lead author Lisa Stolzenberg, a Professor in FIU’s School of International and ... 12 to 17 years who participated in the National Survey on Drug Use ...
(Date:7/1/2015)... ... 2015 , ... Franklin University, one of the leading educators of working adults ... named Dean of the College of Health & Public Administration . ... vision and mission of Franklin University via curriculum planning, course scheduling, faculty staffing and ...
Breaking Medicine News(10 mins):Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Franklin University Appoints Dean of College of Health & Public Administration 2
... NOAA-supported scientists from the Louisiana Universities Marine Consortium and Louisiana ... coast of Louisiana and Texas in the Gulf of Mexico ... researchers are predicting the area could measure a record 8,800 ... 2007, the dead zone was 7,903 square miles. The largest ...
... of Industry ... Standards, ... exchange, today announced it has received full,accreditation by The Electronic Healthcare ... peer,evaluation of an organization,s ability to perform at industry established,levels., ...
... Company (NYSE: PG ) confirmed previously announced sales and ... 2007/08. The company,continues to expect sales growth for the quarter ... with previous guidance and diluted,earnings per share of $0.76 to ... available. P&G is scheduled,to announce the final results for the ...
... PRUSSIA, Pa., July 15 HighPoint Solutions LLC,a ... that it,has been selected by one of the ... a Contract Analytics Reporting & Scorecard solution. This,project ... reports, scorecards and dashboards, resulting in a complete ...
... shown an association between certain past diagnostic radiation procedures ... a rare form of prostate cancer which affects about ... disease. , The study, the first of its kind ... from diagnostic procedures and the risk of prostate cancer, ...
... the University of Warwick have discovered diabetes could be a ... In a study led by Dr Saverio Stranges, Associate Professor ... at levels of oxidative stress in the body (a toxic ... levels of oxidative stress in people with coronary heart disease, ...
Cached Medicine News:Health News:NOAA and Louisiana scientists predict largest Gulf of Mexico 'dead zone' on record 2Health News:Availity Awarded Full EHNAC Accreditation 2Health News:Availity Awarded Full EHNAC Accreditation 3Health News:Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08 2Health News:Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08 3Health News:HighPoint Solutions to Develop Contract Analytics Solution for a Top Three Pharmaceutical Company 2Health News:Possible link found between X-rays and prostate cancer 2
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: